Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide + bupivacaine + epinephrine
- Development stage
- Unknown
- Lead developer
- Eastern Virginia Medical School
- Modality
- Small Molecules
- Administration
- Perineural
01
Overview
triamcinolone acetonide + bupivacaine + epinephrine is a combination drug therapy being investigated by Eastern Virginia Medical School for the treatment of chronic neurogenic cough. The treatment involves a superior laryngeal nerve (SLN) block using a mixture of the corticosteroid triamcinolone acetonide and the local anesthetic bupivacaine with epinephrine. Triamcinolone acts as a glucocorticoid receptor agonist to provide long-term anti-inflammatory effects and reduce neural hypersensitivity, while bupivacaine acts as a sodium channel blocker to provide immediate neural blockade. Epinephrine is included as a vasoconstrictor to prolong the local effect of the anesthetic. This intervention is designed to interrupt the cough reflex arc in patients whose cough is thought to have a neurogenic origin and has failed standard therapies.
- Other names
- Steroid/Anesthesia MixtureSuperior Laryngeal Nerve Block mixtureTriamcinolone/Bupivacaine mixturesteroid + anesthesia-Eastern Virginia Medical School-chronic neurogenic cough
02
Targets
GR (Glucocorticoid receptor)ADRB1 (β1)ADRA1A (α1A)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on triamcinolone acetonide + bupivacaine + epinephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide + bupivacaine + epinephrine.